Workshop on Methods in Supportive Oncology Research

项目总结 尽管对癌症及其治疗的了解有了巨大的进步，但大多数人 癌症患者仍然会感到疲劳、疼痛、焦虑、失眠、抑郁症状和食欲不振。这些 衰弱的症状不仅影响生活质量，还影响医疗保健利用，对癌症的坚持 治疗，甚至可能是生存。支持肿瘤学(姑息治疗、症状管理、 心理社会肿瘤学和生存)旨在解决这些关切。然而，证据基础是 支持性肿瘤学干预措施仍在涌现。有必要进行额外的研究，以指导临床护理和 国际移民组织发现，在支持性肿瘤学方面严重缺乏训练有素的研究人员来满足这一需求。 响应国家呼吁解决这一差距，我们建议更新我们非常成功的癌症 研究教育补助金继续在支持性肿瘤学研究方面培训新的研究人员。在最后一次 四年来，我们通过年度密集的研究研讨会培训了143名初出茅庐的调查人员 支持肿瘤学的方法。参与者显著获得了研究知识和技能，100% 在研讨会结束时完成了研究协议，80%以上的人后来在 他们的本土机构。在研讨会结束后的三年里，2015年第一期课程的参与者获得了 超过2,160万美元的研究资金(当年拨款的直接成本每1美元，回报72美元) 发表了21篇论文，与他们的工作坊课程的新合作者。参与的需求仍然很高。 方法和背景：在五年的时间里，我们计划培训五个班的早期研究人员 不同学科(医生、护士、心理学家和社会工作者)，通过继续年度强化 在波士顿举办为期六天的研讨会，利用两所哈佛机构的资源：马萨诸塞州综合医院 和Dana-Farber癌症研究所(DFCI)。我们的机构承诺是实质性的，包括 哈佛医学院姑息治疗中心承担车间后勤管理。这个 研讨会的主要目标是培训早期研究人员基本研究方法，以支持 肿瘤学，这将使他们能够编写科学严格的研究方案并实施这些方案 在美国各地。在研讨会的每一天，参与者都会参加一系列相关的教学课程 方法和在R01资助的支持性肿瘤学研究人员领导的小写作小组中会面。每天都有 反馈和指导，参与者在六天的时间里写出一份完整的研究方案。 教职员工：我们组建了一支优秀的支持肿瘤学专家团队(已成立 独立研究人员、授权审查员和期刊编辑)来规划、制作和评估研讨会。 作为DFCI和MGH高生产率和著名的支持性肿瘤学项目的领导者，PI(Dr. Pirl和Temel)拥有组织这次研讨会所需的经验和领导技能。

PROJECT SUMMARY Despite dramatic advances in the understanding of cancer and its treatment, the majority of individuals with cancer still suffer from fatigue, pain, anxiety, insomnia, depressive symptoms, and poor appetite. These debilitating symptoms not only affect quality of life, but also impact healthcare utilization, adherence to cancer treatment, and possibly even survival. Supportive oncology (palliative care, symptom management, psychosocial oncology, and survivorship) aims to address these concerns. However, the evidence base for supportive oncology interventions is still emerging. Additional research is necessary to guide clinical care and the IOM identified a critical shortage of trained investigators in supportive oncology to meet this need. Responding to national calls to address this gap, we propose to renew our highly successful Cancer Research Education Grant to continue to train new investigators in supportive oncology research. In the last four years, we trained 143 early-career investigators through an annual intensive workshop on research methods in supportive oncology. Participants significantly gained research knowledge and skills, 100% had completed research protocols at the end of the workshop, and over 80% later implemented these protocols at their home institutions. In the three years after the workshop, participants from the first class in 2015 obtained over $21.6 million in research funding (a return of $72 for every dollar of direct costs of the grant that year) and published 21 papers with new collaborators from their workshop class. Demand to participate remains high. Approach and setting: Over five years, we propose to train five classes of early-stage researchers from diverse disciplines (physicians, nurses, psychologists, and social workers) by continuing an annual intensive six-day workshop in Boston with the resources of two Harvard institutions: Massachusetts General Hospital (MGH) and the Dana-Farber Cancer Institute (DFCI). Our institutional commitment is substantial, including the Harvard Medical School Center for Palliative Care assuming the management of workshop logistics. The primary goal of the workshop is to train early-stage investigators in essential research methods in supportive oncology, which will enable them to write scientifically rigorous study protocols and implement these protocols across the US. Each day of the workshop, participants attend didactic sessions on a broad range of relevant methods and meet in small writing groups led by R01-funded supportive oncology investigators. With daily feedback and mentorship, participants write a complete research protocol over the six days. Faculty: We have assembled an outstanding team of experts in supportive oncology (established independent researchers, grant reviewers, and journal editors) to plan, produce, and evaluate the workshop. As leaders of highly-productive and well-known supportive oncology programs at DFCI and MGH, the PIs (Drs. Pirl and Temel) possess the requisite experience and leadership skills to organize this workshop.